Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Net revenue:      
Total net revenue $ 509,728 $ 484,329 $ 444,448
Cost of revenue 321,832 297,269 258,555
GROSS PROFIT 187,896 187,060 185,893
Operating expenses:      
General and administrative 243,356 221,347 143,794
Research and development 30,326 21,873 8,229
Sales and marketing 67,321 62,594 47,862
Restructuring charges 4,516 0 0
Total operating expenses 345,519 305,814 199,885
LOSS FROM OPERATIONS (157,623) (118,754) (13,992)
Interest expense, net 1,506 5,082 7,019
Other expense (income), net 213 499 (7,906)
Gain on investment in and loan receivable from non-consolidated affiliate, net 0 (109,260) (3,955)
Loss on extinguishment of debt 0 0 1,400
Loss on termination of cash flow hedge 0 0 3,506
Loss before taxes (159,342) (15,075) (14,056)
Income tax benefit (15,092) (6,728) (18,228)
NET (LOSS) INCOME $ (144,250) $ (8,347) $ 4,172
NET (LOSS) INCOME PER SHARE      
Basic (in dollars per share) $ (1.16) $ (0.07) $ 0.04
Diluted (in dollars per share) $ (1.16) $ (0.07) $ 0.04
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING      
Basic (in shares) 124,217 119,962 108,579
Diluted (in shares) 124,217 119,962 111,794
Clinical Services      
Net revenue:      
Total net revenue $ 418,754 $ 404,172 $ 382,337
Pharma Services      
Net revenue:      
Total net revenue $ 90,974 $ 80,157 $ 62,111